Phase 3
Completed N=763
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
Source: ClinicalTrials.gov NCT00231816 ↗Enrolled (actual)
763
Serious AEs
1.5%
Results posted
Dec 2010
Primary outcomePrimary: Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses — 553.5; 588.7 gpELISA units/mL
Summary
The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another vaccine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses |
553.5; 588.7 | — |
Eligibility Criteria
Inclusion Criteria
- Adults 50 years of age or older
Exclusion Criteria
- Prior history of Herpes Zoster (shingles)
- Prior receipt of varicella or zoster vaccine
- Immunosuppressed
Data sourced from ClinicalTrials.gov (NCT00231816). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.